Recent developments in obesity management have been revolutionized by introducing novel glucagon-like peptide-1 (GLP-1) based drugs, such as semaglutide and tirzepatide
Understanding these advancements can help you make informed decisions about your treatment
Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events
How the process works Online intake
This includes water, seltzer, tea, and other beverages
If the use of these medications doesnt coincide with lifestyle and behavioral changes, their long-term impact is likely going to be limited
